FDA advances peptide push to White House

The Food and Drug Administration (FDA) has submitted a peptide interim access policy to the White House for review, according to a recent government filing. The proposed policy would reportedly allow compounding pharmacies to provide access to certain peptides.

The development is part of a broader push involving RFK Jr., highlighting ongoing regulatory and administrative focus on peptide access and compounding practices at the federal level.